Navigation Links
Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
Date:8/28/2007

CHELMSFORD, Mass., Aug. 28 /PRNewswire/ -- Magellan Biosciences, an emerging leader in clinical-diagnostics markets worldwide, announced that Steven E. Diamond, PhD, has joined the company as chief scientific officer. Dr. Diamond comes to Magellan from Siemens Medical Solutions Diagnostics (formerly Bayer Diagnostics), where he was vice president, research and development, for the point-of-care product lines: urinalysis, blood gas, and HbA1c (diabetes testing). In addition to internal product development, Dr. Diamond had an active role in the evaluation and development of external technologies to enhance and extend the company's products for near-patient testing.

"Steve has been a true leader in the point-of-care and near-patient- testing arena -- Magellan's primary focus areas for future growth. Under his stewardship, Bayer successfully developed and launched a suite of market- leading products for near-patient testing. He knows how to shepherd products from concept, through research and development, and onward to product launch - all the way to commercial success," said Magellan President and CEO, Robert J. Rosenthal, PhD. "And he joins Magellan at an ideal time in our company development. We continue to meet our growth goals, and have an excellent track record of developing and commercializing innovative platform products to improve outcomes and serve critical unmet needs in the clinical-diagnostic market. Recent product introductions include ESA's LeadCare(R) II point-of- care system, designed for community-based testing to identify rapidly children with elevated blood-lead levels; Dynex's DS2(TM) ELISA processing system, which brings the power of automation to hospital-based and other lower- throughput labs, and TREK's new Vizion(TM) system, which adds digital-imaging capability to its leading Sensititre(R) system for antibiotics-resistance testing.

Dr. Rosenthal continued, "Steve's charge is to help us build on this success by leveraging our
'/>"/>

SOURCE Magellan Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , Nov. 20, 2014 Polaris ... been dosed in its Phase 1 trial of ... for the treatment of malignant pleural mesothelioma (MPM) ... is conducting clinical trials on ADI-PEG 20, both ... for the treatment of several other indications, including ...
(Date:11/21/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 30, 2014.  Biorem,s complete 2014 third quarter financial statements and MD&A ... Summary:Three-months ended September 30, , Nine-months ended ... 2014 , 2013 , 2014 ... , 6,715 , 14,476 Gross profit , ...
(Date:11/18/2014)... New Orleans, LA (PRWEB) November 17, 2014 ... developer of build-to-order, open architecture blade-based and rackmount ... new NVIDIA® Tesla® K80 dual-GPU accelerator throughout its ... Utilizing a pair of the company’s latest proprietary ... up to eight discrete NVIDIA Tesla K80 dual-GPU ...
(Date:11/18/2014)... November 18, 2014 Alanda Software, ... Transparency Reporting solutions, announced today that a top ... its Consummate Provider™ solution in both the U.S. ... Global, SaaS based, Data Quality remediation portal, designed ... third party Providers improve their ability to capture, ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... Inc. (Nasdaq: EXEL ) today announced that ... Inc. (Hudson, NY) pursuant to which Exelixis,sold Taconic ... GmbH,for approximately $20 million, subject to certain post-closing ... and commercialization of,genetically engineered mouse models and engineered ...
... LAKE, N.J., Nov. 20 Barr,Pharmaceuticals, Inc. (NYSE: ... Barr,Laboratories, Inc., has initiated a challenge of the ... 10mg, 15mg & 20mg. Focalin XR is manufactured ... Holdings Inc. Barr filed its Abbreviated New ...
... FRANKLIN, Mass., Nov. 20 Echo Therapeutics,Inc. (OTC ... quarter ended September 30, 2007. For the quarter ended ... share, compared to $1,390,000 or,$.49 per share, for the ... 30, 2007, net loss was $10,278,000, or $1.05 per ...
Cached Biology Technology:Exelixis Sells 80% Stake in Artemis to Taconic 2Exelixis Sells 80% Stake in Artemis to Taconic 3Exelixis Sells 80% Stake in Artemis to Taconic 4Barr Confirms Patent Challenge of Focalin(R) XR 2Barr Confirms Patent Challenge of Focalin(R) XR 3Echo Therapeutics Reports Third Quarter 2007 Results 2Echo Therapeutics Reports Third Quarter 2007 Results 3Echo Therapeutics Reports Third Quarter 2007 Results 4Echo Therapeutics Reports Third Quarter 2007 Results 5Echo Therapeutics Reports Third Quarter 2007 Results 6
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... was fascinating to put a flashlight up to our ... Washington University in St. Louis engineers are using a ... to improve imaging of cancerous tissues and to develop ... K. Beare Distinguished Professor of Biomedical Engineering at the ... novel time-reversal technology that allows researchers to better focus ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
... Louis, MO, May 11, 2009 As the childhood obesity ... early parent and child behaviors contribute to the problem. A ... in the May/June 2009 issue of the Journal of ... signs of satiety in their infants tend to overfeed them, ...
... world,s second largest fish hide out for half ... on May 7th in Current Biology , a ... the iconic species and highlights just how little we ... the researchers said. "While commonly sighted in surface ...
... team of researchers from the United States, the Netherlands ... that are associated with altered kidney disease risk. One ... protein, the most common protein in the urine of ... for almost 60 years, its functions are not well ...
Cached Biology News:Does mom know when enough is enough? 2Disappearing act of world's second largest fish explained 2Study finds novel genetic risk factors for kidney disease 2
... HistoMark Biotin Streptavidin-HRP Systems provide ... and intracellular antigens in frozen or ... These systems also facilitate double ... can be performed simultaneously with primary ...
Screening test for the detection of Salmonella sp. by means of DNA amplification, subsequent molecular hybridization and detection on a microtitre plate....
... three step procedure (PCR, Exonuclease III digestion ... one day. The typical cloning efficiency using ... Features and Benefits: , , Universal - ... expression vector , High Cloning Efficiency - ...
... Two sizes available for use with 96- or 384-well ... 96 for ease of location on 96-tube plates ... the skirt of the plate* Efficient sealing is ... in conjunction with screw or clip-down hot lid thermal ...
Biology Products: